International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

Estriol: Women's Choice vs. A Manufacturer's Greed

Author(s): Goodrum Jennifer

Issue: Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 286-292

Estriol: Women's Choice vs. A Manufacturer's Greed Page 1

Estriol: Women's Choice vs. A Manufacturer's Greed Page 2

Estriol: Women's Choice vs. A Manufacturer's Greed Page 3

Estriol: Women's Choice vs. A Manufacturer's Greed Page 4

Estriol: Women's Choice vs. A Manufacturer's Greed Page 5

Estriol: Women's Choice vs. A Manufacturer's Greed Page 6

Estriol: Women's Choice vs. A Manufacturer's Greed Page 7

Download in electronic PDF format for $75

Abstract: The U.S. Food and Drug Administration recently took action to†hal4 the compounding of hormone preparations that contain estriol, an action requested in a citizen petition filed by Wyeth Pharmaceuticals. If the Food and Drug Administration, with the support of Wyeth, is successful in its efforts, women throughout the U.S. who rely on compounded hormones containing estriol will have to discontinue their prescribed treatment. The International Academy of Compounding Pharmacists is engaged in ongoing outreach to ensure that members of Congress recognize the importance of protecting pharmacy compounding for the health and well-being of their constituents. Significant progress has been made with the recent introduction of a congressional resolution in support of estriol.

Related Keywords: estriol, U.S. Food and Drug Administration, FDA, regulation, Wyeth, bioidentical hormone replacement therapy, estrogen, BHRT

Related Categories: HRT, LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Estriol: Women's Choice vs. A Manufacturer's Greed Goodrum Jennifer	Jul/Aug 2008 Pg. 286-292
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Deleruyelle Laura J	Sep/Oct 2016 Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 Deleruyelle Laura J	Nov/Dec 2016 Pg. 447-454
Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study Moro Doris, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah	Mar/Apr 2010 Pg. 165-170
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J	Jul/Aug 2004 Pg. 313-319
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3 Deleruyelle Laura J	Jan/Feb 2017 Pg. 6-16
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Ford Gina, Garcia Lea	Jan/Feb 2001 Pg. 52-54
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K	Jan/Feb 2013 Pg. 74-85 View Sample
PreScription: First Estriol, Then What? Allen Loyd V Jr	Jul/Aug 2008 Pg. 284
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Gillson George R, Zava David T	Sep/Oct 2003 Pg. 330-338
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Establishing a Rationale for Compounding Hormone Replacement Therapy Biundo Bruce	May/Jun 2018 Pg. 190-195
Establishing a Rationale for Compounding Hormone Replacement Therapy Biundo Bruce	Jan/Feb 2024 Pg. 22-27
The Politics of Hormone Replacement Therapy Allen Loyd V Jr	Jul/Aug 2007 Pg. 278-281
Bioidentical Hormone Replacement Therapy, Part 2, A Review of Wepfer Scott T	Jan/Feb 2002 Pg. 50-54
Return to Top